OFIX vs. SRDX, ARAY, ANGO, ATRC, ATEC, NVRO, SKIN, IRMD, OSUR, and PLSE
Should you be buying Orthofix Medical stock or one of its competitors? The main competitors of Orthofix Medical include Surmodics (SRDX), Accuray (ARAY), AngioDynamics (ANGO), AtriCure (ATRC), Alphatec (ATEC), Nevro (NVRO), Beauty Health (SKIN), Iradimed (IRMD), OraSure Technologies (OSUR), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
Orthofix Medical presently has a consensus target price of $15.50, indicating a potential upside of 6.75%. Surmodics has a consensus target price of $59.00, indicating a potential upside of 101.09%. Given Surmodics' stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Orthofix Medical.
In the previous week, Surmodics had 4 more articles in the media than Orthofix Medical. MarketBeat recorded 8 mentions for Surmodics and 4 mentions for Orthofix Medical. Surmodics' average media sentiment score of 0.58 beat Orthofix Medical's score of 0.45 indicating that Surmodics is being referred to more favorably in the news media.
Surmodics has a net margin of 3.99% compared to Orthofix Medical's net margin of -20.28%. Surmodics' return on equity of 8.06% beat Orthofix Medical's return on equity.
89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 96.6% of Surmodics shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by insiders. Comparatively, 8.9% of Surmodics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Orthofix Medical received 77 more outperform votes than Surmodics when rated by MarketBeat users. However, 66.80% of users gave Surmodics an outperform vote while only 61.88% of users gave Orthofix Medical an outperform vote.
Orthofix Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Surmodics has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
Summary
Surmodics beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get Orthofix Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OFIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OFIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Orthofix Medical Competitors List
Related Companies and Tools